Regeneron Pharmaceuticals’ (REGN) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a $1,250.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a neutral rating in a research note on Monday, July 22nd. Truist Financial restated a buy rating and set a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. StockNews.com cut shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, September 2nd. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an overweight rating in a report on Friday, August 2nd. Finally, Evercore ISI began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 target price on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of Moderate Buy and an average price target of $1,108.95.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $1,131.50 on Thursday. The firm’s fifty day simple moving average is $1,113.10 and its two-hundred day simple moving average is $1,020.18. The firm has a market capitalization of $124.68 billion, a P/E ratio of 33.43, a P/E/G ratio of 3.13 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 12-month low of $769.19 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the firm earned $8.79 EPS. The business’s quarterly revenue was up 12.3% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,625 shares of company stock valued at $22,298,963. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $932,571,000. Global Assets Advisory LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $339,594,000. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after acquiring an additional 195,902 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after acquiring an additional 184,561 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.